---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-004045"
form_type: "8-K"
ticker: "RAPP"
cik: "0002012593"
company_name: "Rapport Therapeutics, Inc."
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T05:49:07.827858+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Rapport reports positive Phase 1 RAP-219 data; CMO steps down

## Summary
- PET trial: dosing regimen used in Phase 2a epilepsy trial exceeded target receptor occupancy (50-70%) within 5 days.
- MAD-2 trial: no sedation or motoric impairment observed; all adverse events Grade 1 or 2.
- Phase 2a focal epilepsy trial on track; topline data expected mid-2025.
- Bradley Galer, M.D., stepped down as Chief Medical Officer; search for successor underway.

## SEC filing metadata
- accession: 0001193125-25-004045
- form_type: 8-K
- ticker: RAPP
- cik: 0002012593
- company_name: Rapport Therapeutics, Inc.
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2012593/000119312525004045/0001193125-25-004045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2012593/000119312525004045/d925938d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-004045
- JSON: https://secwatch.observer/filing/0001193125-25-004045.json
- Plain text: https://secwatch.observer/filing/0001193125-25-004045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.